Sandoz Maintains Lead On Denosumab With First EU Recommendations
CHMP Positive Opinions Follow Soon After First USFDA Approvals
Executive Summary
Sandoz has again demonstrated its clout in the biosimilars space, taking a major step towards obtaining pan-European marketing authorizations for its biosimilar Prolia/Xgeva products.